LNSR Company Profile and Key Details

LNSR has shown mixed momentum, gaining 3.99% over the past week and 1.27% over the past quarter, though year-to-date performance is up 3.18%. Short-term trend indicators are mixed aligned (SMA20 -2.08%, SMA50 -1.13%, SMA200 -3.17%). The stock’s 14-day RSI is 47.34 (neutral), while the ATR of 0.4 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -31.48% below its high and over 29.19% above its low. Average 10-day trading volume of 29.77 thousand shares is below the 3-month average of 81.34 thousand, indicating normal recent market interest.

LENSAR Inc generated EPS of -$4.39 over the past year. Five-year average earnings growth is -14.63%. The latest quarter delivered EPS of $1.56. The next quarter is forecast at -$0.07. Next year's EPS is expected at $54.00. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $10.00. The high target offers 71.82% upside. The low target suggests 71.82% downside. The mean target is $10.00. This offers 71.82% upside. LENSAR Inc earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 08, 2026, missed forecasts by 743.24%. The prior quarter beat by 80.72%. Over the last six quarters, Apple has recorded several small beats. These include 794.44% in February 27, 2025.

LENSAR Inc has 11.93 million shares outstanding. The public float is 8.64 million shares, elevated short interest at 5.97% of float. This equals 515.99 thousand shares. The short ratio is 7.55 days. Institutional investors hold 59.38% of the float. Insiders own 19.41%. PDL BIOPHARMA, INC. holds 8.67 million shares, STAAB THOMAS R II has 135.13 thousand shares and Winer Gary M has 80.84 thousand shares.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

LENSAR Inc (NASDAQ:LNSR) closed at $5.82 USD, losing -$0.19 (-3.16%) from the previous close of $6.01. The stock is currently mid-range between its 52-week high and low $5.06 and $13.43. With a market capitalization of about $70.45 million, LENSAR Inc is classified as a micro-cap and shows market-like volatility (beta ~0.87). Key stats such as the average daily volume over the past year has been around 81.74 thousand shares, volume is running light vs its 52-week average. Headquartered in Orlando, FL, LENSAR Inc operates in the Healthcare sector and the Medical - Equipment & Services industry. Led by CEO Nicholas T. Curtis, the company employs approximately 150 people and listed since October 02, 2020. LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally.

LENSAR Inc trades at a P/E ratio of 5.94, slightly below the S&P 500 average, with a price-to-sales ratio of 1.22 and a price-to-book ratio of 2.88 suggesting the stock is closer to book value. The P/FCF stands at -5.76, also below market averages.

Our AI price prediction model suggests that LENSAR Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.75%, with price expected at $5.98 by July 27, 2026, within a range of $5.76 to $6.19 3-Month Outlook: Projected fall of -76.8%, reaching $1.35 by October 08, 2026, with a range of $0.65 to $1.48. 1-Year Outlook: Projected loss of -79.04%, with price at $1.22 by July 13, 2027, within a range of $0.00 to $0.00.

LENSAR Inc (NASDAQ:LNSR) shares are flat 3.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows LENSAR Inc trading at a premium to the broader market with a P/E of 5.94. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.25, suggesting 162.03% upside. Our AI forecast model points to short-term strength (2.75% over two weeks), a medium-term fall (-76.8% over three months), and a longer-term loss (-79.04% over one year), with expected trading ranges indicating moderate volatility.